Capital raise secures development of Lipum’s novel drug
Lipum is supported by Horizon 2020, the EU framework program for research and development, and was granted 23 MSEK for the development of a biological pharmaceutical for treatment of chronic inflammatory diseases. In addition to this grant another 25 MSEK was raised in 2019. Now the capital needed to maintain the momentum has been secured in an 8 MSEK share issue.- It has been a turbulent period on the financial market and I am grateful for the support from our shareholders. Current activities will increase our value and an interesting period is ahead of us, says CEO Einar Pontén.
Lipum